Sean Salmon Named Executive Vice President and Group President of Medtronic Diabetes
October 21 2019 - 6:45AM
Medtronic plc (NYSE:MDT) today announced that Sean Salmon,
previously Senior Vice President (SVP) and President, Coronary and
Structural Heart (CSH) within the Cardiac and Vascular Group of
Medtronic, has been named Executive Vice President (EVP) and Group
President of Medtronic Diabetes, effective today. Salmon will serve
on the company’s Executive Committee and succeeds Hooman Hakami,
who is leaving Medtronic.
“I want to thank Hooman for his contributions to
Medtronic over the past five years,” said Omar Ishrak, Chairman and
Chief Executive Officer. ”Under his leadership, our business
introduced the world’s first hybrid closed-loop insulin pump system
– the MiniMed® 670G System – and increased Diabetes Group
revenue by over $700 million. We are excited about the product
pipeline in diabetes, which is the most robust in the business'
history and which will make a real difference to more patients with
diabetes around the world. Hooman's leadership has been
instrumental in advancing our business and achieving these
results."
The company continues to expect the Diabetes Group
to deliver low-single digit organic revenue growth in the current
quarter. To ensure a seamless transition, Hakami will remain an
advisor to executive leadership on an as needed basis through
February 2020.
“Sean is a proven and highly respected leader both
inside and outside of Medtronic, and I am confident in his ability
to deliver continued growth and therapy adoption in our Diabetes
business as he has done with our CSH business,” said Geoff Martha,
Medtronic’s President-elect (effective November 1, 2019) and EVP of
Medtronic’s Restorative Therapies Group. “With our robust
portfolio, our opportunity to serve diabetes patients through new
innovations and services has never been greater. Sean has
consistently demonstrated his ability to bring life-changing
solutions to patients given his extensive knowledge of our
business, his track record of strategy development and execution,
and his well-established commitment to our Mission. I look forward
to working with him in his new role. I also want to thank Hooman
Hakami for his leadership of this important business over the past
five years.”
Salmon joined Medtronic in 2004 and has spent the
past 15 years in increasingly senior management roles. He led
Medtronic’s entry into the highly-competitive drug eluting stent
market and subsequently diversified the business via organic
innovation and acquisitions. He has a proven track record of
building high-performing teams, driving innovation and operating
effectiveness and delivering sustained and profitable growth.
As President of Coronary and Structural Heart,
Salmon led the Coronary and Renal Denervation, Cardiac Surgery and
Structural Heart business units and led numerous functions
including Clinical, Regulatory, R&D, Quality, Health Economics
& Reimbursement, Business Development and Strategy. He led
the expansion of Medtronic’s fast-growing transcatheter aortic
valve replacement (TAVR) business by commercializing multiple
product innovations, extending global penetration and by expanding
treatment indications. Under his leadership, the Coronary and
Structural Heart business grew to $3.7B in revenue with
approximately 11,000 employees and 4.7 million patients
served.
“I am honored and excited to take on leadership of
Medtronic’s market-leading Diabetes business,” said Salmon. “We
have a robust pipeline that promises to improve outcomes while
vastly easing the burden for people living with diabetes. I’m
looking forward to engaging the diabetes community and the people
we serve to ensure that our products, therapies and services meet
their needs.”
Salmon also brings nearly 30 years’ experience in
the medical device and pharmaceutical industries, with previous
roles at CR Bard, Johnson & Johnson, SurgiVision and EuroRSCG
Life. He earned an MBA from the Kellogg School of Management at
Northwestern University and a BS in Applied Physiology from Boston
University.
About the Diabetes Group at
Medtronic(www.medtronicdiabetes.com)Medtronic is working
together with the global community to change the way people manage
diabetes. The company aims to transform diabetes care by expanding
access, integrating care and improving outcomes, so people living
with diabetes can enjoy greater freedom and better health.
About MedtronicMedtronic plc
(www.medtronic.com), headquartered in Dublin, Ireland, is among the
world's largest medical technology, services and solutions
companies - alleviating pain, restoring health and extending life
for millions of people around the world. Medtronic employs more
than 90,000 people worldwide, serving physicians, hospitals and
patients in more than 150 countries. The company is focused on
collaborating with stakeholders around the world to take healthcare
Further, Together.
Any forward-looking statements are subject to
risks and uncertainties such as those described in Medtronic's
periodic reports on file with the Securities and Exchange
Commission. Actual results may differ materially from anticipated
results.
-end-
Rob ClarkPublic Relations+1-763-505-2682
Ryan WeispfenningInvestor Relations+1-763-505-4626
Medtronic (NYSE:MDT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Sep 2023 to Sep 2024